| Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus M Odendahl, A Jacobi, A Hansen, E Feist, F Hiepe, GR Burmester, ... The Journal of Immunology 165 (10), 5970-5979, 2000 | 788 | 2000 |
| European S3‐Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC A Nast, P Gisondi, AD Ormerod, P Saiag, C Smith, PI Spuls, P Arenberger, ... Journal of the European Academy of Dermatology and Venereology 29 (12), 2277 …, 2015 | 541 | 2015 |
| Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis H Bang, K Egerer, A Gauliard, K Lüthke, PE Rudolph, G Fredenhagen, ... Arthritis & Rheumatism 56 (8), 2503-2511, 2007 | 491 | 2007 |
| Emerging cell and cytokine targets in rheumatoid arthritis GR Burmester, E Feist, T Dörner Nature Reviews Rheumatology 10 (2), 77-88, 2014 | 369 | 2014 |
| Rheumatoid factor revisited T Dörner, K Egerer, E Feist, GR Burmester Current opinion in rheumatology 16 (3), 246-253, 2004 | 354 | 2004 |
| Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome A Hansen, M Odendahl, K Reiter, AM Jacobi, E Feist, J Scholze, ... Arthritis & Rheumatism 46 (8), 2160-2171, 2002 | 322 | 2002 |
| Mechanisms, biomarkers and targets for adult-onset Still’s disease E Feist, S Mitrovic, B Fautrel Nature Reviews Rheumatology 14 (10), 603-618, 2018 | 302 | 2018 |
| Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease C Gabay, B Fautrel, J Rech, F Spertini, E Feist, I Kötter, E Hachulla, ... Annals of the rheumatic diseases 77 (6), 840-847, 2018 | 262 | 2018 |
| A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial M Cutolo, GE Myerson, RM Fleischmann, F Lioté, F Díaz-González, ... The Journal of Rheumatology 43 (9), 1724-1734, 2016 | 212 | 2016 |
| Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life … GR Burmester, E Feist, H Kellner, J Braun, C Iking-Konert, A Rubbert-Roth Annals of the rheumatic diseases 70 (5), 755-759, 2011 | 205 | 2011 |
| Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease D Roggenbuck, G Hausdorf, L Martinez-Gamboa, D Reinhold, T Büttner, ... Gut 58 (12), 1620-1628, 2009 | 176 | 2009 |
| Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. K Egerer, U Kuckelkorn, PE Rudolph, JC Rückert, T Dörner, ... The Journal of rheumatology 29 (10), 2045-2052, 2002 | 174 | 2002 |
| Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course L Cavagna, E Trallero-Araguás, F Meloni, I Cavazzana, J Rojas-Serrano, ... Journal of clinical medicine 8 (11), 2013, 2019 | 173 | 2019 |
| Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis I Eshed, E Feist, CE Althoff, B Hamm, E Konen, GR Burmester, ... Rheumatology 48 (8), 887-891, 2009 | 162 | 2009 |
| Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in … GR Burmester, E Feist, MA Sleeman, B Wang, B White, F Magrini Annals of the rheumatic diseases 70 (9), 1542-1549, 2011 | 157 | 2011 |
| Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma C Jakob, K Egerer, P Liebisch, S Türkmen, I Zavrski, U Kuckelkorn, ... Blood 109 (5), 2100-2105, 2007 | 151 | 2007 |
| European S3-Guideline on the systemic treatment of psoriasis vulgaris-Update Apremilast and Secukinumab-EDF in cooperation with EADV and IPC. A Nast, PI Spuls, G Kraaij, P Gisondi, C Paul, AD Ormerod, P Saiag, ... Journal of the European Academy of Dermatology & Venereology 31 (12), 2017 | 144 | 2017 |
| Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus K Egerer, E Feist, U Rohr, A Pruss, GR Burmester, T Dörner Lupus 9 (8), 614-621, 2000 | 144 | 2000 |
| Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests K Egerer, D Roggenbuck, R Hiemann, MG Weyer, T Büttner, B Radau, ... Arthritis research & therapy 12, 1-9, 2010 | 137 | 2010 |
| Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity N Nirmala, A Brachat, E Feist, N Blank, C Specker, M Witt, J Zernicke, ... Pediatric Rheumatology 13, 1-6, 2015 | 135 | 2015 |
